MULTIPLE MYELOMA

Prophylactic treatment with tocilizumab shows promise for reducing a serious adverse effect in multiple myeloma treatment.

The first safety run-in cohort of the MajesTEC-7 trial showed promising safety/efficacy results with teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma.

The IMROZ trial reveals significant improvements in PFS for patients with newly diagnosed, transplant-ineligible multiple myeloma.

Linvoseltamab may have similar — if not better — outcomes compared with teclistamab for patients with triple-class exposed relapsed or refractory multiple myeloma.

Data from DREAMM-7 showed comparable patient-reported outcomes between belantamab/bortezomib/dexamethasone and daratumumab/bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

A step-up dosing regimen of teclistamab with prophylactic tocilizumab for relapsed/refractory multiple myeloma showed promising responses in a small patient cohort.

Treatment with talquetamab demonstrated promising safety and efficacy findings when used in relapsed/refractory multiple myeloma, including patients with comorbidities and poor functional status.

Retreatment with daratumumab showed response rates similar to overall response rates from initial daratumumab-based regimens in a retrospective study.

In a phase 3 trial, BVd demonstrated a substantial improvement in progression-free survival compared with DVd for patients with relapsed/refractory multiple myeloma.

Belantamab mafodotin in combination with other therapies shows promise for patients with multiple myeloma following the first relapse.

The FDA has set a target action date of September 27, 2024, for a decision on the supplemental biologics license application of isatuximab plus bortezomib, lenalidomide, and dexamethasone.

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants about quadruplet vs triplet regimens and the goals of deep responses in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Rahul Banerjee, MD, FACP, physician-researcher at Fred Hutch Cancer Center in Seattle, WA, discusses the potential links between CAR T-cell therapy and secondary T-cell malignancies.

Binod Dhakal, MD, MS, discusses the basis of the FDA approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma that has been treated with at least 1 prior line of therapy and is refractory to lenalidomide.

During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.

C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.

At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Adam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.

Paul Richardson, MD, concludes his conversation by briefly discussing additional trials influencing the multiple myeloma treatment landscape, as well as the use of iberdomide.

Paul Richardson, MD, continues his conversation by highlighting various ongoing studies in the multiple myeloma space.

Paul Richardson, MD, highlights some of the important studies being done in multiple myeloma.

Paul Richardson, MD, delves into some of the studies significantly impacting the multiple myeloma treatment landscape and outcomes for patients.

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.